TITLE

Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study

AUTHOR(S)
Wade, Alan G.; Crawford, Gordon M.; Yellowlees, Ann
PUB. DATE
January 2011
SOURCE
BMC Psychiatry;2011, Vol. 11 Issue 1, p42
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Escitalopram is licensed for use at doses up to 20 mg but is used clinically at higher doses. There is limited published data at higher doses and none in the treatment of Major Depressive Disorder (MDD). Methods: This open-label, pilot study was designed to investigate the efficacy, safety and tolerability of escitalopram in doses up to 50 mg in MDD. It was conducted in 60 primary care patients with MDD who had not responded to adequate treatment with citalopram. Patients were treated with escalating doses of escitalopram up to 50 mg for up to 32 weeks until they achieved remission (Montgomery-Asberg Depression Rating Scale [MADRS] ≤8) or failed to tolerate the dose. Results: Forty-two patients (70%) completed the study. Twenty-one patients (35%) achieved remission with 8 of the 21 patients (38%) needing the 50 mg dose to achieve remission. Median time to remission was 24 weeks and median dose in remission was 30 mg. No significant safety issues were identified although tolerability appeared to decline above a dose of 40 mg with 26% of patients unable to tolerate 50 mg. Twelve (20%) patients had adverse events leading to discontinuation. The most common adverse events were headache (35%), nausea, diarrhoea and nasopharyngitis (all 25%). Minor mean weight gain was found during the study, which did not appear to be doserelated. Half of the patients who completed the study chose to continue treatment with escitalopram rather than taper down the dose at 32 weeks. Conclusions: Dose escalation with escitalopram above 20 mg may have a useful role in the management of patients with MDD, although further studies are needed to confirm this finding.
ACCESSION #
59758232

 

Related Articles

  • Low-dose tricyclics effective for depression. Bailey, R. Eugene; Johnson III, Kenneth M. // Journal of Family Practice;May2003, Vol. 52 Issue 5, p356 

    Minimum effective dosage and ranges for antidepressants have not been established. While studies suggest that lower-dose tricyclic antidepressants (TCAs) may be as effective as higher-dose TCAs, dose comparison studies with other antidepressants have not been conducted. Low-dose TCAs may not be...

  • Duloxetine (Cymbalta) for Treatment of Major Depressive Disorder. Cobb, Carla; Crichlow, Renee // American Family Physician;9/15/2005, Vol. 72 Issue 6, p1099 

    Presents clinical information on the use of duloxetine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of major depressive disorder. Safety of using the drug; Efficacy of the drug; Recommended drug dosage to be administered.

  • Higher dose venlafaxine may improve response compared with standard doses in people with major depressive disorder and intolerance or non-responsiveness to SSRIs. Thase, M. E; Shelton, R. C.; Khan, A. // Evidence Based Mental Health;Feb2007, Vol. 10 Issue 1, p17 

    The article presents a study on the efficacy of higher doses of venlafaxine extended release compared with standard doses for treating adults with major depressive disorder who do not respond to selective serotonin reuptake inhibitor (SSRI) therapy. The study was conducted to 232 adult...

  • Treatment-Resistant Depression in the Clinical Practice of Borderline Psychiatry. Yastrebov, D. // Neuroscience & Behavioral Physiology;Sep2012, Vol. 42 Issue 7, p735 

    Results from studies of the efficacy of venlafaxine in treatment-resistant borderline depression are presented. A total of 30 patients aged 23-63 years with nonpsychotic depression were studied. Because of the absence of efficacy of previous treatment, patients received venlafaxine at doses of...

  • 25 years after Prozac. Hatton, Randy C. // Pharmacy Today;May2013, Vol. 19 Issue 5, p38 

    The article discusses the continued success of Eli Lilly's depression therapy called Prozac, which was launched in 1988. It mentions some of the qualities of the selective serotonin reuptake inhibitor (SSRI) that contributed to its success, such as lack of lethality and ease in dosing....

  • CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy. Bechtholt-Gompf, Anita; Smith, Karen; John, Catherine; Kang, Hannah; Carlezon, William; Cohen, Bruce; Öngür, Dost // Psychopharmacology;Jun2011, Vol. 215 Issue 4, p689 

    Rationale: In patients, ketamine is a fast-acting antidepressant that can induce long-lasting symptom relief. Similar rapid effects have been reported in rodents, but reports of lasting effects are limited. Objectives: We sought to extend past findings by examining dose-response curves that...

  • Vilazodone Effective and Safe in Major Depressive Disorder. Hoyle, Brian // MD Conference Express;Jun2014, Vol. 14 Issue 8, p13 

    A multicenter, randomized, double-blind, placebo-controlled trial involving more than 1100 patients with major depressive disorder has affirmed the efficacy and safety of vilazodone 40 mg/day and indicated the acceptability of a dose of 20 mg/day [APA 2014 (poster NR6-103)].

  • Single-Dose Ketamine Associated with Rapid Improvement of Depressive Symptoms. Nierengarten, Mary Beth // MD Conference Express;Jun2014, Vol. 14 Issue 8, p17 

    Data from a randomized clinical trial show that patients with moderate to severe depressive symptoms treated with a single dose of ketamine show rapid improvement of depressive symptoms compared to patients treated with a psychoactive placebo control. This article discusses outcomes of the...

  • Higher Doses of Levomilnacipran May Benefit Patients with Severe Depression. Parry, Nicola // MD Conference Express;Jun2014, Vol. 14 Issue 8, p20 

    This article presents a poster with results of a Phase 3 trial to evaluate the efficacy and tolerability of levomilnacipran extended-release (ER) dose in adult patients with major depressive disorder [APA 2014 (poster NR6-087); NCT00969709]. The results of the study indicated that higher doses...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics